The gene therapy Zolgensma helped children born with a fatal disease grow up to run and play. But the cost was stunning: $2M per dose. While taxpayers and charities funded the drug’s early development, execs, venture-capital backers and a pharma giant have reaped the profits. (Pub. Feb. 2025)
200 reposts430 likes